Oragenics Inc (OGEN) 1.75 $OGEN
Oragenics (OGEN) in Focus: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 8:39AM CDT
Oragenics Inc. (OGEN) was a big mover last session, as its shares rose roughly 6% on the day.
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8sbsp/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Exploit Technologies Pte Ltd - Piramal Enterprises Limited - Aphios Corporation - Wockhardt Limited - Paratek Pharmaceuticals, Inc. - Alchemia Limited - Immtech Pharmaceuticals, Inc. - Lorus Therapeutics Inc. - NovaBay Pharmaceuticals, Inc. - Oragenics, Inc. - Microbio Co., Ltd. - MicuRx Pharmaceuticals, Inc. - Enanta Pharmaceuticals, Inc. - TAXIS Pharmaceuticals, Inc. - LegoChem Biosciences, Inc - MGB Biopharma Limited - Sentinella Pharmaceuticals, Inc. - Sealife PHARMA GMBH For more information visit http://www.researchandmarkets.com/research/d8...cinresista
Dental Caries - Pipeline Review, H1 2014
M2 - Fri May 30, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tcb7pb/dental_caries) has announced the addition of the "Dental Caries - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Dental Caries, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dental Caries and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Aphios Corporation - Oragenics, Inc. - C3 Jian, Inc - Ensoltek Co., Ltd. Drug Profiles - C-16G2 - SMaRT Replacement Therapy - Asterias - Hesed-2000 - Drugs for Dental Caries For more information visit http://www.researchandmarkets.com/research/tc...tal_caries
'Mad Money' Lightning Round: I Want MasterCard
at The Street - Sat May 24, 5:00AM CDT
Cramer says hold onto Qiagen NV but avoid GameStop.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 23, 6:58PM CDT
The bears being caught with their pants down this week but what happens next week is anyone's guess, Cramer says.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
Oragenics to Present at Biotech Showcase 2014
Business Wire - Tue Jan 14, 7:00AM CST
Oragenics, Inc. (NYSE:MKT - OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced that Dr. John N. Bonfiglio, President and Chief Executive Officer for Oragenics, is scheduled to present at Biotech Showcase(TM) 2014, taking place January 13-15, 2014 in San Francisco, CA. Dr. Bonfiglio will present an update on Oragenics' company strategy and progress on Wednesday, January 15, 2014 at 3:00 p.m. PST to attending investors and pharmaceutical and healthcare executives.
Oragenics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
Business Wire - Mon Jan 13, 1:42PM CST
Oragenics, Inc. (NYSE MKT:OGEN) (the "Company"
today announced that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange" has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity.
RedChip TV Debuts on Bloomberg Asia
GlobeNewswire - Thu Jan 02, 4:06PM CST
RedChip Companies, Inc. ("RedChip" , an international small-cap research, investor relations, and media company, today announced the debut of "The RedChip Money Report: Small Stocks Big Money" on Bloomberg Asia, reaching an additional 14.5 million households.
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGEN)
WorldStockWire - Thu Sep 05, 4:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGENI)
WorldStockWire - Thu Sep 05, 4:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Business Wire - Mon Aug 26, 6:45AM CDT
Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a synthetic biology company, preliminary experiments demonstrate that a genetically-modified (GM) host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.
Intrexon IPO Prices High After Upsizing; Stock Soars
at Investor's Business Daily - Thu Aug 08, 11:28AM CDT
Synthetic-biology startup Intrexon (XON) soared more than 40% on the stock market Thursday after pricing its fattened IPO at the high end of its range. Intrexon priced 10 million shares at $16 apiece to raise $160 million, after last month announcing...
Enterococcus Faecium Infections - Pipeline Review, H2 2012
M2 - Thu Aug 01, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k929nz/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. I also provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Enterococcus Faecium Infections Overview Therapeutics Development An Overview of Pipeline Products for Enterococcus Faecium Infections Companies Involved in Enterococcus Faecium Infections Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Aquapharm Biodiscovery Limited - Ceragenix Pharmaceuticals - Immtech Pharmaceuticals - Lorus Therapeutics - MerLion Pharmaceuticals - MicuRx Pharmaceuticals, Inc - Nabi Biopharmaceuticals - Oragenics, Inc - Paratek Pharmaceuticals - Piramal Healthcare Limited - Trius Therapeutics, Inc - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/k9...terococcus
Oragenics to Join the Russell Microcap(R) Index
Business Wire - Tue Jun 25, 8:31AM CDT
Oragenics, Inc. (NYSE MKT:OGEN), a healthcare company focused on becoming the world leader in novel antibiotics against infectious disease and probiotcs for oral health, announced today that it will be included in the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 28, 2013, according to a preliminary list of additions posted June 21st on www.russell.com/indexes.
Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development
Oragenics Launches New Professional and Consumer Commercial Websites
Business Wire - Thu May 02, 9:50AM CDT
Oragenics, Inc. (NYSE:MKT - OGEN) today announced that it has launched two new websites. The first, www.evorapro.com, is designed to educate dental professionals about the benefits of oral probiotics in maintaining good oral health and balance, while also providing information on becoming a partner with Oragenics and offering its professional strength product, EvoraPro, in their practices.
Oragenics To Present Oral Care Probiotics Seminar at SupplySide MarketPlace 2013
Business Wire - Tue Apr 30, 8:33AM CDT
Oragenics, Inc. (NYSE:MKT: OGEN) today announced that Dr. Martin Handfield, Vice President of R&D for Oragenics, will be presenting a seminar entitled "Oral Care Probiotics Development" on Tuesday, April 30th at 5:00 pm at the SupplySide MarketPlace 2013, taking place from April 30 - May 2 at the Jacob Javits Center in New York, NY. SupplySide MarketPlace 2013 brings together the buyers and sellers that drive the dietary supplement, food, beverage, personal care, cosmetic and animal nutrition marketplaces. The Oragenics seminar is part of a practical short course entitled "Pre- & Probiotics Americas 2013: Pre- & Probiotics - Market, Science, Regulations and Applications" and will focus on describing the fundamental basis of oral probiotics, as well as highlighting the competitive advantage of the Oragenics line of oral care products.
Clostridium Infections - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:16AM CDT
Research and Markets has announced the addition of the "Clostridium Infections - Pipeline Review, H1 2013" (http://www.researchandmarkets.com/research/p9lxmj/clostridium) report to their offering. 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Clostridium Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by u
Oragenics (OGEN) in Focus: Stock Adds 6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 8:39AM CDT
Oragenics Inc. (OGEN) was a big mover last session, as its shares rose roughly 6% on the day.
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d8sbsp/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Exploit Technologies Pte Ltd - Piramal Enterprises Limited - Aphios Corporation - Wockhardt Limited - Paratek Pharmaceuticals, Inc. - Alchemia Limited - Immtech Pharmaceuticals, Inc. - Lorus Therapeutics Inc. - NovaBay Pharmaceuticals, Inc. - Oragenics, Inc. - Microbio Co., Ltd. - MicuRx Pharmaceuticals, Inc. - Enanta Pharmaceuticals, Inc. - TAXIS Pharmaceuticals, Inc. - LegoChem Biosciences, Inc - MGB Biopharma Limited - Sentinella Pharmaceuticals, Inc. - Sealife PHARMA GMBH For more information visit http://www.researchandmarkets.com/research/d8...cinresista
Dental Caries - Pipeline Review, H1 2014
M2 - Fri May 30, 8:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tcb7pb/dental_caries) has announced the addition of the "Dental Caries - Pipeline Review, H1 2014" report to their offering. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. This report provides comprehensive information on the therapeutic development for Dental Caries, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dental Caries and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Aphios Corporation - Oragenics, Inc. - C3 Jian, Inc - Ensoltek Co., Ltd. Drug Profiles - C-16G2 - SMaRT Replacement Therapy - Asterias - Hesed-2000 - Drugs for Dental Caries For more information visit http://www.researchandmarkets.com/research/tc...tal_caries
'Mad Money' Lightning Round: I Want MasterCard
at The Street - Sat May 24, 5:00AM CDT
Cramer says hold onto Qiagen NV but avoid GameStop.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri May 23, 6:58PM CDT
The bears being caught with their pants down this week but what happens next week is anyone's guess, Cramer says.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
Oragenics to Present at Biotech Showcase 2014
Business Wire - Tue Jan 14, 7:00AM CST
Oragenics, Inc. (NYSE:MKT - OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced that Dr. John N. Bonfiglio, President and Chief Executive Officer for Oragenics, is scheduled to present at Biotech Showcase(TM) 2014, taking place January 13-15, 2014 in San Francisco, CA. Dr. Bonfiglio will present an update on Oragenics' company strategy and progress on Wednesday, January 15, 2014 at 3:00 p.m. PST to attending investors and pharmaceutical and healthcare executives.
Oragenics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
Business Wire - Mon Jan 13, 1:42PM CST
Oragenics, Inc. (NYSE MKT:OGEN) (the "Company"
today announced that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange" has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity. RedChip TV Debuts on Bloomberg Asia
GlobeNewswire - Thu Jan 02, 4:06PM CST
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced the debut of "The RedChip Money Report: Small Stocks Big Money" on Bloomberg Asia, reaching an additional 14.5 million households. OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGEN)
WorldStockWire - Thu Sep 05, 4:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGENI)
WorldStockWire - Thu Sep 05, 4:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Business Wire - Mon Aug 26, 6:45AM CDT
Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a synthetic biology company, preliminary experiments demonstrate that a genetically-modified (GM) host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.
Intrexon IPO Prices High After Upsizing; Stock Soars
at Investor's Business Daily - Thu Aug 08, 11:28AM CDT
Synthetic-biology startup Intrexon (XON) soared more than 40% on the stock market Thursday after pricing its fattened IPO at the high end of its range. Intrexon priced 10 million shares at $16 apiece to raise $160 million, after last month announcing...
Enterococcus Faecium Infections - Pipeline Review, H2 2012
M2 - Thu Aug 01, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k929nz/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. I also provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Enterococcus Faecium Infections Overview Therapeutics Development An Overview of Pipeline Products for Enterococcus Faecium Infections Companies Involved in Enterococcus Faecium Infections Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Aquapharm Biodiscovery Limited - Ceragenix Pharmaceuticals - Immtech Pharmaceuticals - Lorus Therapeutics - MerLion Pharmaceuticals - MicuRx Pharmaceuticals, Inc - Nabi Biopharmaceuticals - Oragenics, Inc - Paratek Pharmaceuticals - Piramal Healthcare Limited - Trius Therapeutics, Inc - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/k9...terococcus
Oragenics to Join the Russell Microcap(R) Index
Business Wire - Tue Jun 25, 8:31AM CDT
Oragenics, Inc. (NYSE MKT:OGEN), a healthcare company focused on becoming the world leader in novel antibiotics against infectious disease and probiotcs for oral health, announced today that it will be included in the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 28, 2013, according to a preliminary list of additions posted June 21st on www.russell.com/indexes.
Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development
Oragenics Launches New Professional and Consumer Commercial Websites
Business Wire - Thu May 02, 9:50AM CDT
Oragenics, Inc. (NYSE:MKT - OGEN) today announced that it has launched two new websites. The first, www.evorapro.com, is designed to educate dental professionals about the benefits of oral probiotics in maintaining good oral health and balance, while also providing information on becoming a partner with Oragenics and offering its professional strength product, EvoraPro, in their practices.
Oragenics To Present Oral Care Probiotics Seminar at SupplySide MarketPlace 2013
Business Wire - Tue Apr 30, 8:33AM CDT
Oragenics, Inc. (NYSE:MKT: OGEN) today announced that Dr. Martin Handfield, Vice President of R&D for Oragenics, will be presenting a seminar entitled "Oral Care Probiotics Development" on Tuesday, April 30th at 5:00 pm at the SupplySide MarketPlace 2013, taking place from April 30 - May 2 at the Jacob Javits Center in New York, NY. SupplySide MarketPlace 2013 brings together the buyers and sellers that drive the dietary supplement, food, beverage, personal care, cosmetic and animal nutrition marketplaces. The Oragenics seminar is part of a practical short course entitled "Pre- & Probiotics Americas 2013: Pre- & Probiotics - Market, Science, Regulations and Applications" and will focus on describing the fundamental basis of oral probiotics, as well as highlighting the competitive advantage of the Oragenics line of oral care products.
Clostridium Infections - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:16AM CDT
Research and Markets has announced the addition of the "Clostridium Infections - Pipeline Review, H1 2013" (http://www.researchandmarkets.com/research/p9lxmj/clostridium) report to their offering. 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Clostridium Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by u
